Press Release: aap: Q2/2015 sales above guidance at EUR 6.5 million; 27% LOQTEQ(R) growth in H1/2015

aap Implantate AG / aap: Q2/2015 sales above guidance at EUR 6.5 million; 27% LOQTEQ(R) growth in H1/2015 . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.

aap Implantate AG (XETRA: AAQ.DE) generated sales totalling EUR 6.5 million in the second quarter of 2015 (Q2/2014: EUR 8.1 million) according to preliminary figures, thereby exceeding the guidance provided in May of EUR 5.0 million to EUR 6.1 million. Total sales in the first half of the current financial year thus amounted to EUR 13.6 million (H1/2014: EUR 14.2 million).

Sales in EUR million Q2/2015 Q2/2014 Change Trauma 3.2 2.9 8% thereof LOQTEQ(R) 2.0 1.8 15% Biomaterials 3.2 4.9 -34% Projects 0.0 0.1 -82% Other 0.1 0.2 -50% Total sales 6.5 8.1 -20%

Sales in EUR million H1/2015 H1/2014 Change Trauma 5.6 5.1 11% thereof LOQTEQ(R) 3.7 2.9 27% Biomaterials 7.6 8.4 -9% Projects 0.2 0.2 10% Other 0.2 0.5 -72% Total sales 13.6 14.2 -4%

In the second quarter of 2015, aap

Implantate AG increased its LOQTEQ(R) portfolio sales by 15% compared to the corresponding period in the last year to EUR 2.0 million (Q2/2014: EUR 1.8 million). Sustained by the positive sales development of the LOQTEQ(R) product family, overall sales in the trauma business were up by 8% year-on-year to EUR 3.2 million (Q2/2014: EUR 2.9 million).

In the biomaterials business the company generated sales of EUR 3.2 million (Q2/2014: EUR 4.9 million) in the second quarter of the current financial year. This decline was merely a quarterly fluctuation primarily due to the ordering behaviour of the major customers in the area of bone cement and mixing systems.

In the first half of 2015 aap

Implantate AG continued the positive sales development of the LOQTEQ(R) portfolio with an increase of 27% year-on-year to EUR 3.7 million (H1/2014: EUR 2.9 million). In the biomaterials business the company realized sales of EUR 7.6 million (H1/2014: EUR 8.4 million) in the first six months of the current financial year.

The preliminary results contained in this press release are based on management's initial analysis of operations for the period ended on 30 June 2015, and are therefore subject to change. aap

Implantate AG plans to announce its final results for the second quarter respectively the first half of 2015 on 14 August 2015.

About aap Implantate AG

aap Implantate AG is a globally operating medical device company headquartered in Berlin, Germany. The company develops, manufactures and markets trauma and biomaterials products for orthopedics. The trauma portfolio includes besides the innovative anatomical plating system LOQTEQ(R) a wide range of cannulated screws as well as standard plates and screws. In the biomaterials business the company is specialized on bone cements and mixing systems. In German-speaking countries aap Implantate AG directly sells its trauma products to hospitals, buying syndicates and hospital groups while it uses a broad network of distributors in more than 60 countries at the international level. In the biomaterials business sales are handled via OEM and private label cooperations with several selected international orthopedic and trauma companies. aap Implantate AG's stock is listed in the Prime Standard segment of Frankfurt Stock Exchange (XETRA: AAQ.DE). For more information, please visit www.aap.de, or download the Company's investor relations app from the Apple's App Store or Google Play.

Forward-looking statement

This release may contain forward-looking statements based on current experience, estimates and projections of the management board and currently available information. They are not guarantees of future performance. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. Many factors could cause the actual results, performance or achievements of aap to be materially different from those that may be expressed or implied by such statements. These factors include those discussed in aap's public reports. Forward-looking statements therefore speak only as of the date they are made. aap does not assume any obligation to update the forward-looking statements contained in this release or to conform them to future events or developments.

For inquiries please contact: aap Implantate AG, Fabian Franke, Investor Relations, Lorenzweg 5, 12099 Berlin, Germany

Tel.: +49 30 7501 9-134, fax: +49 30 7501 9-290, e-mail: f.franke@aap.de

This announcement is distributed by Nasdaq OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: aap Implantate AG via Globenewswire

HUG#1939102

--- End of Message ---

aap Implantate AG

Lorenzweg 5 Berlin Germany

WKN: 506660;ISIN: DE0005066609;

Listed: Freiverkehr in Börse Stuttgart,

Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg,

Freiverkehr in Börse Berlin,

Freiverkehr in Börse Düsseldorf,

Freiverkehr in Bayerische Börse München,

Freiverkehr in Niedersächsische Börse zu Hannover,

Prime Standard in Frankfurter Wertpapierbörse,

Regulierter Markt in Frankfurter Wertpapierbörse;

http://www.aap.de (END) Dow Jones Newswires

   July 16, 2015 09:40 ET (13:40 GMT)- - 09 40 AM EDT 07-16-15